Quick Answer
Spyre Therapeutics, Inc. reported Total Revenue of $0.00 for fiscal year 2025.
Spyre Therapeutics, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $0.00 | — |
| 2024 | $0.00 | -100.0% |
| 2023 | $886.0K | -62.0% |
| 2022 | $2.33M | -87.6% |
| 2021 | $18.74M | — |
| 2020 | $0.00 | — |
| 2019 | $0.00 | -100.0% |
| 2018 | $3.89M | -25.3% |
| 2017 | $5.21M | +12.5% |
| 2016 | $4.63M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | $0.00 | — | — |
| June 30, 2024 | $0.00 | -100.0% | — |
| March 31, 2024 | $0.00 | -100.0% | — |
| September 30, 2023 | $0.00 | -100.0% | -100.0% |
| June 30, 2023 | $688.0K | +10.1% | +247.5% |
| March 31, 2023 | $198.0K | -85.5% | +13.8% |
| September 30, 2022 | $174.0K | -87.6% | -72.2% |
| June 30, 2022 | $625.0K | -95.4% | -54.1% |
- Over the 2016–2025 period, Spyre Therapeutics, Inc.’s total revenue has declined by 100.0% (from $4.63 million to $0.00).
- The most recent figure is from Spyre Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: